Research graph
References from Weekly long-acting growth hormone versus daily growth hormone therapy on quality of life, efficacy, and safety in children with short stature: a systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency
10.1159/000452150 · 2016 · External reference
Advances in differential diagnosis and management of growth hormone deficiency in children
10.1038/s41574-021-00539-5 · 2021 · External reference
Isolated growth hormone deficiency (GHD) in childhood and adolescence: Recent advances
10.1210/er.2013-1067 · 2014 · External reference
Short and long-term effects of growth hormone in children and adolescents with GH deficiency
10.3389/fendo.2021.720419 · 2021 · External reference
Idiopathic short stature: What to expect from genomic investigations
10.3390/endocrines4010001 · 2023 · External reference
Approach to the growth hormone-deficient child during transition to adulthood
10.1210/jc.2007-0167 · 2007 · External reference
The continuum between GH deficiency and GH insensitivity in children
10.1007/s11154-020-09590-5 · 2021 · External reference
Growth hormone therapy in children and adults
2007 · External reference
Understanding the growth hormone therapy adherence paradigm: A systematic review
10.1159/000350251 · 2013 · External reference
Monitoring of concordance in growth hormone therapy
10.1136/adc.2006.114249 · 2008 · External reference
Long-acting growth hormone preparations - Current status and future considerations
10.1210/clinem/dgz149 · 2020 · External reference
Long-acting growth hormone preparations in the treatment of children
10.17458/per.vol16.2018.lh.longactingghpreparation · 2018 · External reference
Long-term pegylated GH for children with GH deficiency: A large, prospective, real-world study
10.1210/clinem/dgad039 · 2023 · External reference
Temporal structure of in vivo growth hormone secretory events in humans
10.1152/ajpendo.1991.260.1.e101 · 1991 · External reference
The current state of long-acting growth hormone preparations for growth hormone therapy
10.1097/med.0000000000000416 · 2018 · External reference
Long-acting growth hormone therapy in pediatric growth hormone deficiency: A consensus statement
10.1210/clinem/dgae834 · 2025 · External reference
Human growth and growth hormone: From antiquity to the recominant age to the future
10.3389/fendo.2021.709936 · 2021 · External reference
Comparative efficacy and safety of once-weekly pegylated recombinant human growth hormone versus daily growth hormone therapy in children: A systematic review and meta-analysis
10.3390/jcm14248740 · 2025 · External reference
Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis
10.1016/j.phrs.2023.106805 · 2023 · External reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations
10.7326/m14-2385 · 2015 · External reference
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
10.1136/bmj.d5928 · 2011 · External reference
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
2009 · External reference
Meta-analysis in clinical trials
10.1016/0197-2456(86)90046-2 · 1986 · External reference
The interpretation of random-effects meta-analysis in decision models
10.1177/0272989x05282643 · 2005 · External reference
Analyzing data and undertaking meta-analyses
10.1002/9780470712184.ch9 · 2008 · External reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · 2003 · External reference
Assessing the influence of a single study in meta-analysis
1999 · External reference
Interaction revisited: The difference between two estimates
10.1136/bmj.326.7382.219 · 2003 · External reference
Bias in meta-analysis detected by a simple, graphical test
10.1136/bmj.315.7109.629 · 1997 · External reference
Operating characteristics of a rank correlation test for publication bias
10.2307/2533446 · 1994 · External reference
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
10.1007/978-1-4020-8486-7_10 · 2000 · External reference
Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)
10.1210/jc.2011-2234 · 2012 · External reference
Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency
10.1530/eje-13-0148 · 2013 · External reference
24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency
10.1210/jc.2013-2502 · 2014 · External reference
Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: Phase II and phase III multicenter, randomized studies
10.1530/eje-16-0905 · 2017 · External reference
A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency
10.1210/jc.2016-3776 · 2017 · External reference
Long-acting C-terminal peptide-modified hGH (MOD-4023): Results of a safety and dose-finding study in GHD children
10.1210/jc.2016-3547 · 2017 · External reference
Once-weekly administration of sustained-release growth hormone in Korean prepubertal children with idiopathic short stature: A randomized, controlled phase II study
10.1159/000489262 · 2018 · External reference
12-month effects of once-weekly and twice-monthly administration of hybrid Fc-fused human growth hormone, GX-H9, treatment in pediatric with GHD deficiency
2018 · External reference
Use of PEGylated recombinant human growth hormone in Chinese children with growth hormone deficiency: A 24-month follow-up study
10.1155/2019/1438723 · 2019 · External reference
Once-weekly somapacitan vs daily GH in children with GH deficiency: Results from a randomized phase 2 trial
10.1210/clinem/dgz310 · 2020 · External reference
First report of disease-specific patient reported outcomes from a randomized phase 2 trial of once-weekly somapacitan versus daily GH in children with GHD
10.1210/jendso/bvaa046.603 · 2020 · External reference
Reduced effectiveness and comparable safety in biweekly vs. weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency: A phase IV non-inferiority threshold targeted trial
10.3389/fendo.2021.779365 · 2021 · External reference
Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: The phase 3 heiGHt trial
10.1530/ey.19.4.8 · 2021 · External reference
Study on the efficacy and safety of long-acting growth hormones in treating pediatric growth hormone deficiency patients
2021 · External reference
Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: A phase 3 study
10.1530/ey.20.2.8 · 2022 · External reference
Evaluation of quality of life in pre-pubertal children using the quality of life in short stature youth (qolissy) questionnaire, following 12 months of growth hormone treatment with either a weekly somatrogon or a daily genotropin injection schedule
10.1016/j.jval.2020.08.601 · 2020 · External reference
Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin
10.1080/03007995.2023.2290623 · 2024 · External reference
Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin®) in Japanese children with pediatric growth hormone deficiency: Results from a randomized phase 3 study
10.1159/000524600 · 2022 · External reference
Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency
10.1515/jpem-2021-0735 · 2022 · External reference
First clinical study on long-acting growth hormone therapy in children with Turner sydrome
10.1055/a-1842-0724 · 2022 · External reference
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial
10.1111/cen.15025 · 2024 · External reference
Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study
10.1007/s00431-024-05719-9 · 2024 · External reference
A novel Y-shaped pegylated recombinant human growth hormone for children with growth hormone deficiency
10.1210/clinem/dgae816 · 2025 · External reference
Somapacitan is effective and well tolerated in Chinese children with growth hormone deficiency: A randomized controlled phase 3 study
10.1159/000545786 · 2025 · External reference
Efficacy of different measures of long-acting growth hormone in treating children with short stature
10.1080/17520363.2025.2587570 · 2025 · External reference
Somapacitan in children with idiopathic short stature: a randomized controlled phase 3 study
10.1093/ejendo/lvag027 · 2026 · External reference
Once-weekly lonapegsomatropin was efficacious and well tolerated in Chinese children with growth hormone deficiency: Results from a phase 3 randomized trial
10.1159/000550980 · 2026 · External reference
Weekly pegylated recombinant human growth hormone for prepubertal children with growth hormone deficiency: adherence advantage drives superior short-term efficacy over daily rhGH
10.21037/tp-2025-1-935 · 2026 · External reference
Extension of the phase 3 trial of somatrogon in children with growth hormone deficiency: 3 years of safety and efficacy
10.1159/000552183 · 2026 · External reference
Real world performance of once weekly somatrogon on naive patients with isolated growth hormone deficiency: Mind the weight gain
10.1016/j.ghir.2026.101714 · 2026 · External reference
Comparative efficacy and safety of Jintrolong and other long-acting growth hormones for growth hormone deficiency in East Asia: A systematic review and network meta-analysis
10.1016/j.eprac.2026.03.096 · 2026 · External reference
Long-acting growth hormone for treating growth hormone deficiency in children: a meta-analysis of randomized controlled trials focusing on changes in body mass index
10.1210/clinem/dgag093 · 2026 · External reference
Treatment with long-acting growth hormone: effectiveness and safety
10.3389/fendo.2026.1818944 · 2026 · External reference
Long-acting growth hormone in idiopathic short stature
10.1159/000490115 · 2018 · External reference
Novel therapies for growth disorders
10.1007/s00431-023-05239-y · 2024 · External reference
Long-acting growth hormone preparations and their use in children with growth hormone deficiency
10.1159/000523791 · 2023 · External reference
The science behind the relations among cancer, height, growth patterns, and growth hormone axis
10.1530/erc-22-0400 · 2023 · External reference
IGF-I and breast cancer: a meta-analysis
10.1002/ijc.20233 · 2004 · External reference
Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies
10.1002/ijc.24927 · 2010 · External reference
A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk
10.1158/0008-5472.can-15-1551 · 2016 · External reference
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
10.1530/ey.19.9.1 · 2022 · External reference
Evaluation of glucose metabolism in children with growth hormone deficiency during long-term growth hormone treatment
10.26402/jpp.2018.2.08 · 2018 · External reference
